Motoneuronotrophic factor (MNTF)

Motoneuronotrophic factor (MNTF) is an endogenous neurotrophic factor and master regulator of the human nervous system, primarily expressed during embryonic development with peak levels around the ninth week of gestation [1, 8, 21]. It plays a critical role in the differentiation, survival, and maintenance of motor neurons, as well as in axon regeneration and the modulation of inflammatory and apoptotic pathways [7, 23]. MNTF acts by binding to the beta subunits of the insulin receptor (IR), insulin-like growth factor 1 receptor (IGF1R), and IGF2 receptor (IGF2R), triggering signaling cascades that restore cellular homeostasis [2, 20, 29]. In neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and Parkinson's disease, MNTF-based therapies aim to provide neuroprotection and slow disease progression by regulating the expression of multiple disease-associated genes, including SOD1 and TDP-43 [4, 12, 28]. The drug candidate GM604 (also known as GM6) is a synthetic 6-amino-acid peptide analog of MNTF designed to mimic its neuroprotective effects and cross the blood-brain barrier [5, 10, 25]. Clinical trials have suggested that modulating MNTF pathways can lead to favorable shifts in biomarkers and improved clinical measures in patients with progressive neurological conditions [2, 3, 22].

Other names

MNTF1MNTF2MNTF33merGM604GM6GM602GM608

Binds to the beta subunit of the tyrosine kinase of the Insulin Receptor (IR), Insulin-like Growth Factor 1 Receptor (IGF1R), and IGF2 Receptor (IGF2R). It acts as a master regulator that modulates the expression of multiple disease-associated genes and pathways to restore cellular homeostasis.